CClinicalTrials.gg
Active, not recruitingNCT07437599Updated Jun 22, 2026

Effect of Coffee Smelling on Pain, Physiological Parameters and Time to Discharge From Post Anesthesia Care Unit in Patients Undergoing Laparoscopic Cholecystectomy

An interventional study of Coffee Smell and Placebo in Cholecystectomy, Laparoscopic, sponsored by Istanbul University - Cerrahpasa. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Istanbul University - Cerrahpasa · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Jun 2026, 3 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This research was designed as a randomized controlled trial to determine the effects of coffee sniffing on pain and physiological parameters in patients undergoing cholecystectomy surgery.

Read the detailed description

Study Variables: The independent variables of the study are the participant's age, gender, height, weight, smoking, and alcohol use; the dependent variables are the length of stay in the Post-anesthesia care unit (PACU) after anesthesia, the Modified Aldrete score, the pain score (numeric rating scale), and physiological values.

Study Location and Time: This study is planned to be conducted at Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine Hospital PACU, between February 2026 and August 2026.

Study Population: The study population will consist of patients who underwent cholecystectomy surgery and received general anesthesia with the same anesthesia protocol at Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine Hospital PACU.

Data Collection Tools: A Patient Demographic Information Form, created by the researcher in accordance with the literature, will be used for data collection. The Modified Aldrete Score and the Visual Analog Scale, both valid and reliable, will be used.

02

Conditions studied

  • Cholecystectomy, Laparoscopic

Keywords

  • Postanesthesia Nursing
  • Laparoscopic Cholecystectomy
  • Coffee
03

In context

Lead sponsor

Istanbul University - Cerrahpasa is the lead sponsor of 680 studies on the registry; 208 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Being 18 years of age or older,
  • Having no prior history of surgery,
  • Having undergone laparoscopic cholecystectomy surgery,
  • Being physically and mentally able to communicate,
  • Having received the same anesthesia protocol,
  • Having no known allergy or sensitivity to the smell of coffee,
  • Being willing and cooperative to smell coffee for the specified duration in the experimental group,
  • Providing written consent after being informed about the study,
  • Having an ASA I or II rating.

Exclusion criteria

Exclusion Criteria:

  • The following are contraindications for a patient's sense of smell:
  • No complications developing during surgery,
  • No indication for postoperative intensive care,
  • Special circumstances (pregnancy, etc.),
  • Being under active treatment for depression, anxiety, or other psychiatric disorders,
  • Having anatomical abnormalities that may cause a problem with the sense of smell.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Coffee Smelling Group

    The patient inhales the scent of coffee for 3-5 minutes using a cotton pad.

    Behavioral: Coffee Smell

  • Placebo comparator
    Placebo Group

    The patient inhales an empty cotton bag for 3-5 minutes.

    Behavioral: Placebo

Interventions

  • BehavioralCoffee Smell

    The patient inhales the scent of coffee for 3-5 minutes using a cotton pad.

  • BehavioralPlacebo

    The patient inhales an empty cotton bag for 3-5 minutes.

06

What researchers measure

Primary outcomes

  1. Modified Aldrete Score

    The Modified Aldrete Score is a clinical scoring system used to assess a patient's recovery and readiness for discharge from the post-anesthesia care unit (PACU) based on activity, respiration, circulation, consciousness, and oxygen saturation. Ensures objective and standardized assessment of postoperative recovery Reduces risk of premature discharge from PACU Enhances patient safety by identifying respiratory, cardiovascular, or neurological instability Provides measurable criteria for clinical decision-making Commonly, a score of ≥ 9 indicates readiness for PACU discharge.

    Time frame: This is the period from post-operative time until discharge from the PACU unit. (min. 20/min- max 60/min).

  2. NRS (numeric rating scale)

    The Numeric Rating Scale (NRS) is a simple, closed-ended survey tool that asks respondents to assign a number to measure feelings, preferences, or symptoms. It is widely used across healthcare, market research, and customer service to translate subjective experiences into quantifiable, easy-to-analyze data. 0-10 Scale (Pain Management): The most common format. In clinical settings, the Numeric Pain Rating Scale (NPRS) asks patients to rate pain from 0 ("no pain") to 10 ("worst possible pain").

    Time frame: This is the period from post-operative time until discharge from the PACU unit. (min. 20/min- max 60/min).

07

Study locations

1 site
  • Istanbul University Cerrahpasa
    Istanbul, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07437599
Lead sponsor
Istanbul University - Cerrahpasa
Responsible party
Emre Kugu (PhD. Student, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Feb 27, 2026
Start date
Feb 22, 2026
Primary completion
Jun 30, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Jun 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion